Insider Selling: SI-BONE, Inc. (NASDAQ:SIBN) Insider Sells 3,311 Shares of Stock

SI-BONE, Inc. (NASDAQ:SIBN - Get Free Report) insider Anthony J. Recupero sold 3,311 shares of the firm's stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $14.15, for a total value of $46,850.65. Following the sale, the insider now owns 284,555 shares of the company's stock, valued at $4,026,453.25. This represents a 1.15 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

SI-BONE Stock Up 6.6 %

SI-BONE stock traded up $0.86 during trading hours on Wednesday, hitting $13.92. The company had a trading volume of 604,374 shares, compared to its average volume of 361,946. SI-BONE, Inc. has a fifty-two week low of $11.70 and a fifty-two week high of $19.16. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. The firm has a market capitalization of $590.95 million, a P/E ratio of -15.13 and a beta of 1.02. The firm's fifty day moving average is $15.81 and its 200-day moving average is $14.65.

SI-BONE (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.05. The company had revenue of $49.00 million during the quarter, compared to the consensus estimate of $48.87 million. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. On average, research analysts forecast that SI-BONE, Inc. will post -0.78 earnings per share for the current year.

Remove Ads

Analysts Set New Price Targets

Several equities analysts have recently commented on SIBN shares. Needham & Company LLC upped their target price on SI-BONE from $20.00 to $24.00 and gave the company a "buy" rating in a report on Tuesday, February 25th. Cantor Fitzgerald restated an "overweight" rating and issued a $25.00 target price on shares of SI-BONE in a research report on Tuesday, February 25th. Finally, Truist Financial reaffirmed a "buy" rating and set a $22.00 price target (up previously from $18.00) on shares of SI-BONE in a report on Tuesday, February 25th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $24.40.

Institutional Investors Weigh In On SI-BONE

Institutional investors and hedge funds have recently modified their holdings of the business. Charles Schwab Investment Management Inc. lifted its position in shares of SI-BONE by 1.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 315,092 shares of the company's stock worth $4,405,000 after buying an additional 5,966 shares during the last quarter. FMR LLC boosted its position in SI-BONE by 103.6% during the third quarter. FMR LLC now owns 2,354 shares of the company's stock worth $33,000 after purchasing an additional 1,198 shares during the period. BNP Paribas Financial Markets grew its holdings in SI-BONE by 24.6% during the third quarter. BNP Paribas Financial Markets now owns 106,442 shares of the company's stock valued at $1,488,000 after purchasing an additional 21,012 shares during the last quarter. Walleye Capital LLC bought a new position in shares of SI-BONE in the third quarter valued at approximately $144,000. Finally, Janus Henderson Group PLC lifted its stake in shares of SI-BONE by 90.4% in the third quarter. Janus Henderson Group PLC now owns 22,582 shares of the company's stock worth $316,000 after buying an additional 10,721 shares during the last quarter. Institutional investors and hedge funds own 98.11% of the company's stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.